J&J’s Spravato Surpasses $1 Billion in Revenue for 2024

Revenue Milestone:
Johnson & Johnson's depression nasal spray, Spravato, achieved $1 billion in revenue in 20242.

Growth Drivers:
The growth was part of J&J's innovative medicines division, which saw a 7.5% increase in sales to $59.96 billion for the full year 20244.

Future Projections:
J&J expects Spravato to deliver peak sales of $1 billion to $5 billion, with the company's 2027 forecast being 50% higher than analyst estimates1.

Market Performance:
The drug's success contributed to J&J's overall revenue growth, with full-year revenues increasing 4.3% to $88.8 billion in 20244.

Portfolio Expansion:
J&J continues to expand its neuroscience portfolio, recently acquiring Intra-Cellular Therapies for $14 billion to bolster its brain health prospects5.

Sources:

1. https://www.fiercepharma.com/pharma/jpm24-johnson-johnson-ceo-says-tecvayli-talvey-and-several-other-meds-can-vastly-outperform

2. https://firstwordpharma.com

4. https://www.fiercepharma.com/pharma/jj-stands-sales-growth-ambitions-and-points-potential-tremfya-boon-stelara-biosimilars-take

5. https://medcitynews.com/2025/01/johnson-and-johnson-intra-cellular-acquisition-caplyta-depression-neuroscience-jnj-itci/